Endo, Inc.

Report azionario OTCPK:ENDP.Q

Capitalizzazione di mercato: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Crescita futura

Criteri Future verificati 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Endo International.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.5%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

None

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Endo International non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:ENDP.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20232,012-2,448341435N/A
9/30/20232,070-252334430N/A
6/30/20232,160-942285391N/A
3/31/20232,182-2,84721130N/A
12/31/20222,319-2,910166269N/A
9/30/20222,552-3,22111110N/A
6/30/20222,783-2,552-980N/A
3/31/20222,928-681277369N/A
12/31/20212,993-569326411N/A
9/30/20212,964129484569N/A
6/30/20212,827109345429N/A
3/31/20212,801137506579N/A
12/31/20202,903247327402N/A
9/30/20202,908-102195268N/A
6/30/20203,002-75299378N/A
3/31/20203,014-190180251N/A
12/31/20192,914-3613098N/A
9/30/20192,936-418108190N/A
6/30/20192,952-52263135N/A
3/31/20192,967-47747128N/A
12/31/20182,947-962177267N/A
9/30/20182,929-968238329N/A
6/30/20182,971-921324434N/A
3/31/20183,132-1,565311435N/A
12/31/20173,469-1,233428554N/A
9/30/20173,942-4,294N/A507N/A
6/30/20174,039-4,386N/A309N/A
3/31/20174,084-3,300N/A742N/A
12/31/20164,010-3,224N/A528N/A
9/30/20163,842553N/A683N/A
6/30/20163,704-59N/A698N/A
3/31/20163,518-539N/A106N/A
12/31/20153,269-300N/A119N/A
9/30/20152,858-725N/A-75N/A
6/30/20152,766128N/A310N/A
3/31/20152,624260N/A492N/A
12/31/20142,38158N/A338N/A
9/30/20142,303-643N/A277N/A
6/30/20142,310-637N/A141N/A
3/31/20142,429-650N/A124N/A
12/31/20132,125189N/A299N/A
9/30/20132,621-628N/A711N/A
6/30/20132,711-629N/A683N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista ENDP.Q è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di ENDP.Q cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di ENDP.Q cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di ENDP.Q cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di ENDP.Q cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ENDP.Q è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/05/02 07:23
Prezzo dell'azione a fine giornata2024/05/02 00:00
Utili2023/12/31
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Endo, Inc. è coperta da 32 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research